REYVOW® (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study

- REYVOW Showed Significant Therapeutic Gains of 17-21% for Pain Freedom at 2 Hours and Met All 18 Gated Endpoints INDIANAPOLIS , Sept. 11, 2020 /PRNewswire/ -- Adults who took REYVOW™ (lasmiditan) C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 4.6 times greater odds,